CYP19A1 and polycystic ovary syndrome: The co-treatment of OX1Ra + OX2Ra or together with NK1Ra in the PCOS groups resulted in a marked elevation in the expression of Cyp19a1 compared to the PCOS control group (P = 0.018 and P = 0.003, respectively) (Fig. 5B), while the expression of Star seems to be unaffected (Fig. 5A).